CHD Vendée

Running trials

• Not yet recruiting

  Bacterial Decolonization to Prevent Severe Radiation Dermatitis in Head and Neck Squamous Cell Carcinoma

  NCT07888907· Source

• Not yet recruiting

  Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).

  NCT07624799· Phase 2· Source

• Not yet recruiting

  PRIMUS : Real World Usage for Real World Evidence of CDSS Use in Multiple Sclerosis

  NCT07647952· Source

• Recruiting

  Study of Alloknesia in Atopic Dermatitis

  NCT06923202· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Source

• Recruiting

  Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia

  NCT07099443· Source

• Not yet recruiting

  Efficacy of Live Online Course Mindfulness Program on Perceived Fatigue in Hemodialysis Patients

  NCT07054112· Source

• Recruiting

  Assessement of Effectiveness of Seawater Nasal Sprays on Sinonasal Symptoms

  NCT07262450· Source

• Recruiting

  Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  NCT06937099· Phase 3· Source

• Recruiting

  Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  NCT06937086· Phase 3· Source

• Recruiting

  Initial Standardized Global Review in Axial Spondyloarthritis

  NCT07141017· Source

• Not yet recruiting

  Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)

  NCT06931704· Phase 2· Source

• Recruiting

  Prospective Multicenter Study of the Relationship Between Virological Effectiveness and Compliance in HIV-1-infected Patients Treated With Bictegravir

  NCT06902142· Source

• Recruiting

  Impact of Pain From Injectables Antiretroviral Treatments in HIV-1 Patients Based on the Injection Site (Ventrogluteal or Dorsogluteal) and the Use or Non-use of Virtual Reality Headset

  NCT06834113· Source

• Not yet recruiting

  Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)

  NCT06663189· Phase 3· Source

• Active, not recruiting

  Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

  NCT06353022· Phase 2· Source

• Active, not recruiting

  Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

  NCT06183489· Phase 2· Source

• Recruiting

  CARE1 Pragmatic Clinical Trial

  NCT06364631· Phase 3· Source

• Recruiting

  Influence of Sodium Intake in spondyLoarthriTes

  NCT06259890· Source

• Recruiting

  AFU Registry of the Therapeutic Management and Follow-up of Non-Muscle-Invasive Bladder Cancer

  NCT05002556· Source

• Recruiting

  Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer

  NCT05706779· Phase 2· Source

• Active, not recruiting

  Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma

  NCT05208086· Source

• Recruiting

  De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

  NCT05255302· Phase 2/3· Source

• Active, not recruiting

  Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

  NCT05169567· Phase 3· Source

• Recruiting

  Evaluation of Omentopexy on Gastro-oesophageal Reflux Following Sleeve Gastrectomy

  NCT04994665· Source

• Active, not recruiting

  Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.

  NCT04823377· Source

• Active, not recruiting

  PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS

  NCT04664465· Source

• Active, not recruiting

  Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)

  NCT01817192· Phase 4· Source

• Recruiting

  A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases

  NCT04299646· Phase 2· Source

• Active, not recruiting

  LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy

  NCT04166604· Phase 2· Source

• Active, not recruiting

  Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.

  NCT04144387· Source

• Active, not recruiting

  An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients

  NCT03606577· Phase 2· Source

• Active, not recruiting

  Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

  NCT03766763· Phase 2· Source

• Recruiting

  Dat'Aids Prevention

  NCT03795376· Source

• Active, not recruiting

  Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction

  NCT03734198· Phase 2· Source

• Active, not recruiting

  A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

  NCT03706365· Phase 2/3· Source

• Recruiting

  REal World Data in LYmphoma and Survival in Adults

  NCT03869619· Source

• Recruiting

  Quality of Care in French HIV Infected Patients

  NCT02898987· Source

• Active, not recruiting

  PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patients aged 70 and older

  NCT02355379· Phase 2· Source

• Active, not recruiting

  A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

  NCT02246621· Phase 3· Source

• Active, not recruiting

  A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer

  NCT01957436· Phase 3· Source

• Recruiting

  COsegregation of VARiants in Panel of Genes

  NCT01689584· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• HIV4 recruiting
• Obesity3 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Kidney cancer2 recruiting
• Multiple sclerosis2 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Bladder cancer1 recruiting
• Chronic kidney disease1 recruiting
• Colorectal cancer1 recruiting
• Crohn's disease1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Follicular lymphoma1 recruiting
• Head and neck cancer1 recruiting
• Hodgkin lymphoma1 recruiting
• Lung cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Multiple myeloma1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

  NCT05625087· Phase 2· Source

• Completed

  Intubation of Obese Patients in the Operating Room With or Without Face Mask Ventilation

  NCT05930678· Source

• Completed

  An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

  NCT05848258· Phase 2· Source

• Completed

  Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

  NCT05665348· Phase 2/3· Source

• Completed

  Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis

  NCT05642208· Phase 4· Source

• Completed

  Aging With HIV and Neurocognitive Decline, a Follow-up Study

  NCT05385588· Source

• Completed

  Evaluation of an Environmental Counsellor's Home Stay in Children Treated for Asthma or Allergic Rhinitis Via a Standardized Medical Questionnaire Randomized Controlled Superiority Trial in Parallel Arms, Multicentric (EvalPCE)

  NCT04927689· Source

• Completed

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· Phase 3· Source

• Completed

  Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology

  NCT03948724· Source

• Completed

  Neuropsychological Development and Executive Functioning of Children Born to HIV- Infected Mothers ( NEUROPSY-HEU )

  NCT04108728· Source

• Completed

  Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia

  NCT04010968· Phase 2· Source

• Terminated

  "Impact of Pelvic Floor Prehabilitation Using Biofeedback on the Severity of the Low Anterior Resection Syndrome in Patients Undergoing a Total Mesorectal Excision for Rectal Cancer"

  NCT03876561· Source

• Completed

  Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis

  NCT03445845· Phase 4· Source

• Completed

  Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr

  NCT03469960· Phase 3· Source

• Completed

  FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

  NCT03584711· Phase 2· Source

• Completed

  Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders

  NCT03227419· Phase 4· Source

• Completed

  Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

  NCT03072238· Phase 3· Source

• Completed

  PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA

  NCT03006432· Phase 3· Source

• Completed

  Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance

  NCT02896582· Phase 2· Source

• Completed

  SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

  NCT02117167· Phase 2· Source

• Completed

  A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

  NCT01740427· Phase 3· Source